Latent autoimmune diabetes in the adults (LADA) in Asia: from pathogenesis and epidemiology to therapy

被引:38
作者
Guglielmi, Chiara [1 ]
Palermo, Andrea [1 ]
Pozzilli, Paolo [1 ,2 ]
机构
[1] Univ Campus Bio Med, Dept Endocrinol & Diabet, I-00128 Rome, Italy
[2] Queen Marys Univ London, Ctr Diabet, Barts & London Sch Med & Dent, London, England
关键词
LADA; epidemiology; pathogenesis; therapy; BETA-CELL-MASS; GLUTAMIC-ACID DECARBOXYLASE; DOUBLE-BLIND; GENETIC-CHARACTERISTICS; ROSIGLITAZONE PREVENTS; INSULIN INTERVENTION; HIGH-TITER; AUTOANTIBODIES; IMMUNOMODULATION; PIOGLITAZONE;
D O I
10.1002/dmrr.2345
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabetes mellitus is a metabolic disorder resulting from a defect in insulin secretion, insulin action or both. An effect of this process is chronic hyperglycaemia with disorder of carbohydrate, fat and protein metabolism and with long-term complications of diabetes including retinopathy, nephropathy and neuropathy. Latent autoimmune diabetes in adults (LADA) is a type of autoimmune diabetes that resembles Type 1 diabetes (T1D), however, it shows a later onset and slower progression towards insulin necessity. Epidemiological studies suggest that LADA may account for 212% of all cases of diabetes in adult population. The epidemiology and phenotypic characteristics of LADA may vary between Caucasian and Asian diabetic patients as lifestyle, food habits and body mass index differ between these two populations. Data on LADA from population-based studies in Asia are sparse and only few studies have looked at it. A number of attractive therapeutic interventions may be envisaged for prevention of beta-cell loss in LADA, including hypoglycaemic and immunomodulatory agents. Because the autoimmune process in LADA seems to be slower than in childhood T1D, there is a wider window of opportunities for intervention. In deciding the best therapeutic approach, features of LADA should guide therapy including presence of other comorbidities that may influence the therapeutic choice.
引用
收藏
页码:40 / 46
页数:7
相关论文
共 64 条
[31]   Clinical and genetic characteristics of diabetic patients with high-titer (>10,000 U/m1) of antibodies to glutamic acid decarboxylase [J].
Ishii, M ;
Hasegawa, G ;
Fukui, M ;
Obayashi, H ;
Ohta, M ;
Ogata, M ;
Yoshioka, K ;
Kitagawa, Y ;
Nakano, K ;
Yoshikawa, T ;
Nakamura, N .
IMMUNOLOGY LETTERS, 2005, 99 (02) :180-185
[32]   Effect of prophylactic insulin treatment on the number of ER-MP23(+) macrophages in the pancreas of NOD mice. Is the prevention of diabetes based on beta-cell rest? [J].
Jansen, A ;
Rosmalen, JGM ;
HomoDelarche, F ;
Dardenne, R ;
Drexhage, HA .
JOURNAL OF AUTOIMMUNITY, 1996, 9 (03) :341-348
[33]   Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM [J].
Kobayashi, T ;
Nakanishi, K ;
Murase, T ;
Kosaka, K .
DIABETES, 1996, 45 (05) :622-626
[34]   IMMUNOGENETIC AND CLINICAL CHARACTERIZATION OF SLOWLY PROGRESSIVE IDDM [J].
KOBAYASHI, T ;
TAMEMOTO, K ;
NAKANISHI, K ;
KATO, N ;
OKUBO, M ;
KAJIO, H ;
SUGIMOTO, T ;
MURASE, T ;
KOSAKA, K .
DIABETES CARE, 1993, 16 (05) :780-788
[35]  
Kobayashi T, 2002, ANN NY ACAD SCI, V958, P117
[36]  
Kobayashi T., 2001, Diabetes-Metabolism Research and Reviews, V17, pS29
[37]  
Lee Seung-Hwan, 2009, Diabetes Res Clin Pract, V83, pe62, DOI 10.1016/j.diabres.2008.11.031
[38]   Clinical review: Type 1 diabetes and latent autoimmune diabetes in adults: One end of the rainbow [J].
Leslie, RDG ;
Williams, R ;
Pozzilli, P .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (05) :1654-1659
[39]   Metabolic Syndrome in Adult-Onset Latent Autoimmune Diabetes [J].
Li, Xia ;
Zhou, Zhiguang ;
Huang, Gan ;
Su, Heng ;
Yan, Xiang ;
Yang, Lin .
METABOLIC SYNDROME AND RELATED DISORDERS, 2005, 3 (02) :174-180
[40]   β-cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1 [J].
Li, YH ;
Cao, XM ;
Li, LX ;
Brubaker, PL ;
Edlund, H ;
Drucker, DJ .
DIABETES, 2005, 54 (02) :482-491